Vnitr Lek 2001, 47(9):627-633
[News in oral antidiabetic therapy].
- Interní hematoonkologická klinika FN Brno, pracovistĕ Bohunice.
Klíčová slova: Administration, Oral; Carbamates, administration & dosage, ; Diabetes Mellitus, drug therapy, ; Humans; Hypoglycemic Agents, administration & dosage, ; Pioglitazone; Piperidines, administration & dosage, ; Rosiglitazone; Thiazoles, administration & dosage, ; Thiazolidinediones
In this article two new peroral antidiabetics are introduced. The first is repaglinide, a prandial glucose regulator. The second is rosiglitazone, a member of the thiazolidinediones family, which improves the sensitivity of tissues to insulin and reduces insulin resistance.
Keywords: Administration, Oral; Carbamates /administration & dosage/; Diabetes Mellitus /drug therapy/; Humans; Hypoglycemic Agents /administration & dosage/; Pioglitazone; Piperidines /administration & dosage/; Rosiglitazone; Thiazoles /administration & dosage/; Thiazolidinediones
Zveřejněno: 1. září 2001 Zobrazit citaci